Cytovia Therapeutics Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with University of California San Francisco (UCSF), New York Stem Cell Foundation (NYSCF), National Cancer Institute, Hebrew University of Jerusalem, and CytoImmune. Therapeutics. Learn more at www.cytoviatx.com
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Florida
Company HQ Country:
United States
Year Founded:
June 2019
Main Therapeutic Focus:
Oncology
Lead Product in Development:
iPSC NK cell
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
5